Standard Dose Ivermectin for COVID-19.
作者信息
Buonfrate Dora, Bisoffi Zeno
机构信息
Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy; Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
出版信息
Chest. 2021 May;159(5):2111-2112. doi: 10.1016/j.chest.2021.03.003.
Abstract
摘要
相似文献
1
Standard Dose Ivermectin for COVID-19.用于治疗新冠肺炎的标准剂量伊维菌素
Chest. 2021 May;159(5):2111-2112. doi: 10.1016/j.chest.2021.03.003.
2
A five-day course of ivermectin may reduce the duration of COVID-19 illness.为期五天的伊维菌素疗程可能会缩短新冠病毒疾病的病程。
Int J Infect Dis. 2021 Sep;110:93-94. doi: 10.1016/j.ijid.2021.07.050. Epub 2021 Jul 26.
3
Ivermectin for COVID-19: Promising but not yet conclusive.用于治疗新冠肺炎的伊维菌素：有前景但尚无定论。
S Afr Med J. 2021 Jan 12;111(3):13187. doi: 10.7196/SAMJ.2021.v111i3.15522.
4
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.连续高剂量伊维菌素对急性髓性白血病患者似乎是安全的，可为新冠病毒感染的临床药物重新利用提供依据。
Leuk Lymphoma. 2020 Oct;61(10):2536-2537. doi: 10.1080/10428194.2020.1786559. Epub 2020 Jul 1.
5
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.开发一种最小生理基于药代动力学模型，以模拟新冠肺炎药物再利用中经口给予伊维菌素后人体肺部的暴露情况。
J Pharm Sci. 2020 Dec;109(12):3574-3578. doi: 10.1016/j.xphs.2020.08.024. Epub 2020 Sep 4.
6
Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).关于伊维菌素对2019年冠状病毒病有效性的回顾性分析（ICON研究）的评论
Chest. 2021 May;159(5):2110-2111. doi: 10.1016/j.chest.2020.10.088.
7
Response.
Chest. 2021 May;159(5):2112-2113. doi: 10.1016/j.chest.2020.11.017.
8
Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.伊维菌素在新冠肺炎晚期的抗炎活性可能反映了全身甘氨酸受体的激活。
Open Heart. 2021 Apr;8(1). doi: 10.1136/openhrt-2021-001655.
9
[Not Available].
Rev Med Suisse. 2021 May 19;17(739):1002-1003.
10
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.伊维菌素治疗可能改善新冠病毒肺炎患者的预后。
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbr.2020.08.011. Epub 2020 Dec 14.
引用本文的文献
1
Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis.伊维菌素抑制 NLRP3 炎性小体可改善博来霉素诱导的肺纤维化。
J Zhejiang Univ Sci B. 2023 Jul 1;24(8):723-733. doi: 10.1631/jzus.B2200385.
2
Ivermectin Effect on In-Hospital Mortality and Need for Respiratory Support in COVID-19 Pneumonia: Propensity Score-Matched Retrospective Study.伊维菌素对 COVID-19 肺炎住院死亡率和呼吸支持需求的影响：倾向评分匹配回顾性研究。
Viruses. 2023 May 10;15(5):1138. doi: 10.3390/v15051138.
3
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.大剂量伊维菌素早期治疗 COVID-19（COVER 研究）：一项随机、双盲、多中心、II 期、剂量探索、概念验证临床试验。
Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6.
本文引用的文献
1
Latin America's embrace of an unproven COVID treatment is hindering drug trials.拉丁美洲对一种未经证实的新冠治疗方法的接受正在阻碍药物试验。
Nature. 2020 Oct;586(7830):481-482. doi: 10.1038/d41586-020-02958-2.
2
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.使用伊维菌素与 COVID-19 住院患者的死亡率降低相关：COVID-19 中的伊维菌素研究。
Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
3
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
4
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤稿——羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册研究分析
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
5
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
Zotero 插件